Angitia Biopharmaceuticals is a clinical-stage biotechnology company that specializes in the discovery and development of innovative therapeutics aimed at addressing significant unmet medical needs in serious musculoskeletal diseases. Founded in 2018, the company focuses on a range of conditions, including degenerative disc disease, osteoporosis, osteogenesis imperfecta, bone metastasis, nonunion, osteoarthritis, and various muscle disorders. Angitia's commitment to advancing patient care is underscored by its team's extensive experience and scientific expertise in novel drug development, which positions the company to deliver breakthrough therapies for patients suffering from these debilitating conditions.

One of Angitia's key products is AGA2118, which is currently undergoing a Phase 2 clinical trial for the treatment of osteoporosis. The trial is being conducted in both the United States and Europe, reflecting the company's global reach and dedication to rigorous clinical research. Recent presentations at the ASBMR 2024 conference highlighted first-in-human data on AGA2118, showcasing the company's commitment to transparency and collaboration within the scientific community. Through its innovative pipeline, Angitia Biopharmaceuticals aims to make significant contributions to the field of musculoskeletal health, ultimately improving the quality of life for patients affected by these serious diseases.

China

Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. With the team’s experience and scientific expertise in new drug development, Angitia is dedicated to bringing innovative therapeutics to help patients in need. 

Angitia Biopharmaceuticals

Company Details